Cargando…
Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors
Cancer diagnostics and therapies have improved steadily over the last few decades, markedly increasing life expectancy for patients at all ages. However, conventional and newer anti-neoplastic therapies can cause short- and long-term cardiotoxicity. The clinical implications of this cardiotoxicity b...
Autores principales: | Bansal, Neha, Adams, M. Jacob, Ganatra, Sarju, Colan, Steven D., Aggarwal, Sanjeev, Steiner, Rudolf, Amdani, Shahnawaz, Lipshultz, Emma R., Lipshultz, Steven E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048046/ https://www.ncbi.nlm.nih.gov/pubmed/32154024 http://dx.doi.org/10.1186/s40959-019-0054-5 |
Ejemplares similares
-
Cardiovascular Effects in Childhood Cancer Survivors Treated with Anthracyclines
por: Franco, Vivian I., et al.
Publicado: (2011) -
Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series
por: Ganatra, Sarju, et al.
Publicado: (2019) -
Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity
por: Chung, Woo-Baek, et al.
Publicado: (2016) -
Current Views on Anthracycline Cardiotoxicity in Childhood Cancer Survivors
por: Sadurska, Elżbieta
Publicado: (2015) -
Cardiotoxicity of Anthracyclines
por: Cardinale, Daniela, et al.
Publicado: (2020)